Literature DB >> 18334759

Co-localization and distribution of cerebral APP and SP1 and its relationship to amyloidogenesis.

Brian Brock1, Riyaz Basha, Katie DiPalma, Amy Anderson, G Jean Harry, Deborah C Rice, Bryan Maloney, Debomoy K Lahiri, Nasser H Zawia.   

Abstract

Alzheimer's disease is characterized by amyloid-beta peptide (Abeta)-loaded plaques in the brain. Abeta is a cleavage fragment of amyloid-beta protein precursor (APP) and over production of APP may lead to amyloidogenesis. The regulatory region of the APP gene contains consensus sites recognized by the transcription factor, specificity protein 1 (SP1), which has been shown to be required for the regulation of APP and Abeta. To understand the role of SP1 in APP biogenesis, herein we have characterized the relative distribution and localization of SP1, APP, and Abeta in various brain regions of rodent and primate models using immunohistochemistry. We observed that overall distribution and cellular localization of SP1, APP, and Abeta are similar and neuronal in origin. Their distribution is abundant in various layers of neocortex, but restricted to the Purkinje cell layer of the cerebellum, and the pyramidal cell layer of hippocampus. These findings suggest that overproduction of Abeta in vivo may be associated with transcriptional pathways involving SP1 and the APP gene.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18334759      PMCID: PMC5862394          DOI: 10.3233/jad-2008-13108

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  51 in total

Review 1.  Neuropathologic changes in Alzheimer's disease.

Authors:  Gary L Wenk
Journal:  J Clin Psychiatry       Date:  2003       Impact factor: 4.384

2.  Cloning by recognition site screening of two novel GT box binding proteins: a family of Sp1 related genes.

Authors:  G Hagen; S Müller; M Beato; G Suske
Journal:  Nucleic Acids Res       Date:  1992-11-11       Impact factor: 16.971

3.  Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain.

Authors:  J T Kadonaga; K R Carner; F R Masiarz; R Tjian
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

4.  Consistent immunohistochemical detection of intracellular beta-amyloid42 in pyramidal neurons of Alzheimer's disease entorhinal cortex.

Authors:  Michael R D'Andrea; Robert G Nagele; Hoau-Yan Wang; Daniel H S Lee
Journal:  Neurosci Lett       Date:  2002-11-29       Impact factor: 3.046

5.  Accumulation of the amyloid-beta precursor protein in multivesicular body-like organelles.

Authors:  Marcel M Verbeek; Irene Otte-Höller; Jack A M Fransen; Robert M W de Waal
Journal:  J Histochem Cytochem       Date:  2002-05       Impact factor: 2.479

6.  A phosphorylated, carboxy-terminal fragment of beta-amyloid precursor protein localizes to the splicing factor compartment.

Authors:  Zoia Muresan; Virgil Muresan
Journal:  Hum Mol Genet       Date:  2004-01-13       Impact factor: 6.150

7.  Functional characterization of the 5' flanking region of the BACE gene: identification of a 91 bp fragment involved in basal level of BACE promoter expression.

Authors:  Yuan-Wen Ge; Bryan Maloney; Kumar Sambamurti; Debomoy K Lahiri
Journal:  FASEB J       Date:  2004-04-01       Impact factor: 5.191

8.  Gene structure and organization of the human beta-secretase (BACE) promoter.

Authors:  Kumar Sambamurti; Rachel Kinsey; Bryan Maloney; Yuan-Wen Ge; Debomoy K Lahiri
Journal:  FASEB J       Date:  2004-04-01       Impact factor: 5.191

Review 9.  Alzheimer's disease with spastic paresis and cotton wool type plaques.

Authors:  Takeshi Tabira; De Hua Chui; Hiroshi Nakayama; Shigetoshi Kuroda; Makoto Shibuya
Journal:  J Neurosci Res       Date:  2002-11-01       Impact factor: 4.164

10.  Sp3 and sp4 transcription factor levels are increased in brains of patients with Alzheimer's disease.

Authors:  Stéphanie Boutillier; Béatrice Lannes; Luc Buée; André Delacourte; Caroline Rouaux; Michel Mohr; Jean-Pierre Bellocq; François Sellal; Yves Larmet; Anne-Laurence Boutillier; Jean-Philippe Loeffler
Journal:  Neurodegener Dis       Date:  2007-10-09       Impact factor: 2.977

View more
  10 in total

1.  Alterations of zinc transporter proteins ZnT-1, ZnT-4 and ZnT-6 in preclinical Alzheimer's disease brain.

Authors:  Ganna Lyubartseva; Jennifer L Smith; William R Markesbery; Mark A Lovell
Journal:  Brain Pathol       Date:  2009-04-07       Impact factor: 6.508

2.  Lifespan profiles of Alzheimer's disease-associated genes and products in monkeys and mice.

Authors:  Remi Dosunmu; Jinfang Wu; Lina Adwan; Bryan Maloney; Md Riyaz Basha; Christopher A McPherson; G Jean Harry; Deborah C Rice; Nasser H Zawia; Debomoy K Lahiri
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

3.  Tolfenamic acid reduces tau and CDK5 levels: implications for dementia and tauopathies.

Authors:  Lina Adwan; Gehad M Subaiea; Riyaz Basha; Nasser H Zawia
Journal:  J Neurochem       Date:  2014-10-18       Impact factor: 5.372

4.  Tolfenamic acid downregulates BACE1 and protects against lead-induced upregulation of Alzheimer's disease related biomarkers.

Authors:  Lina Adwan; Gehad M Subaiea; Nasser H Zawia
Journal:  Neuropharmacology       Date:  2014-01-21       Impact factor: 5.250

5.  Infantile exposure to lead and late-age cognitive decline: relevance to AD.

Authors:  Syed Waseem Bihaqi; Azadeh Bahmani; Gehad M Subaiea; Nasser H Zawia
Journal:  Alzheimers Dement       Date:  2013-07-15       Impact factor: 21.566

6.  Functional characterization of three single-nucleotide polymorphisms present in the human APOE promoter sequence: Differential effects in neuronal cells and on DNA-protein interactions.

Authors:  Bryan Maloney; Yuan-Wen Ge; Ronald C Petersen; John Hardy; Jack T Rogers; Jordi Pérez-Tur; Debomoy K Lahiri
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-01-05       Impact factor: 3.568

7.  Short-term treatment with tolfenamic acid improves cognitive functions in Alzheimer's disease mice.

Authors:  Gehad M Subaiea; Lina I Adwan; Aseef H Ahmed; Karen E Stevens; Nasser H Zawia
Journal:  Neurobiol Aging       Date:  2013-04-30       Impact factor: 4.673

8.  Mithramycin A Alleviates Cognitive Deficits and Reduces Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease.

Authors:  Chao Wei; Wei Zhang; Qiong Zhou; Chao Zhao; Ying Du; Qi Yan; Zhuyi Li; Jianting Miao
Journal:  Neurochem Res       Date:  2016-04-12       Impact factor: 3.996

9.  PuF, an antimetastatic and developmental signaling protein, interacts with the Alzheimer's amyloid-β precursor protein via a tissue-specific proximal regulatory element (PRE).

Authors:  Debomoy K Lahiri; Bryan Maloney; Jack T Rogers; Yuan-Wen Ge
Journal:  BMC Genomics       Date:  2013-01-31       Impact factor: 3.969

Review 10.  Fenamates as Potential Therapeutics for Neurodegenerative Disorders.

Authors:  Jaunetta Hill; Nasser H Zawia
Journal:  Cells       Date:  2021-03-22       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.